Les Tillack is the CEO of Luina Bio, and spearheads the team’s innovation and committed pursuit to world class research, design and sector excellence. This Biotech expert brings over two decades of biopharmaceutical sector experience, and his industry leader reputation, to lead the organisation in world class service delivery. He also brings with him perseverance, innovation and unparalleled experience.

From less than humble beginnings, Les began working in the area of clinical pathology, with Dr Sullivan and Nicolaides Pathology, where he instituted important research projects for the Department of Primary Industries, and the University of Queensland. Then, moving to Progen Pharmaceuticals, Les took a position as Director of Operations, where he led the ground breaking Progen anti-cancer drug, PI-88s, and its progression from preclinical stage, to phase three manufacturing. Les then led a management buyout of Progen’s production site to give rise to Luina Bio.Les now sits proudly as the CEO and Managing Director of Luina Bio Australia’s frontrunner in the biopharmaceutical contract manufacturing space. His role centres on delivering the expansion of Luina Bio’s services and ensuring that our services continually adapts to the needs of our customers.

Les’ commitment and continual strive for excellence underpins his strategic advocacy to the biotechnology industry through new drug development. Les prides himself on the contributions and advancements he and Luina Bio are making for the health and wellbeing of the local and global community. In 2017, Luina Bio won the Queensland Export Award for Health & Biotechnology.
Les’ qualifications include, a Bachelor of Science (B.Sc.) in Microbiology, and a Bachelor of Engineering (B.E.) in Chemical Engineering from the University of Queensland.